Indian paediatric rheumatologists discuss early diagnosis and management of rheumatic disorders in children to prevent organ ...

Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...

Patients with asthma demonstrate a heightened risk for developing osteoarthritis, a relationship that is particularly ...

Researchers have found in a new research that HLA-B27 genetic marker is linked to a higher risk of various arthropathies, ...

Organon’s workforce cuts come several months after the company’s loss of exclusivity to its second-largest product, Atozet.

Organon (OGN) stock in focus as the Merck (MRK) spinoff buys rights to Biogen's (BIIB) biosimilar Tofidence, targeting ...

Tofidence is indicated in certain patients for the treatment of moderate to severe rheumatoid arthritis, giant cell arteritis ...

Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to ...

ST. LOUIS - With nearly 1.5 million people suffering from rheumatoid and juvenile arthritis in the United States, researchers ...

HLA-B27 positivity is linked to higher odds of non-remission in patients with juvenile idiopathic arthritis at 18 years after ...

New research highlights how juvenile idiopathic arthritis (JIA) delays puberty, with disease severity, corticosteroid use, ...

I Gedeon Richter Plc. announces today that the European Medicines Agency has accepted Richter’s marketing authorization application (MAA) for ...